REVB Revelation Bio: רווח למניה בשנים עשר החודשים האחרונים

Revelation Biosciences is developing immunotherapy where formula approvals will provide massive profit leverage with low costs. The net income per share over the last 12 months demonstrates current trends, with -42.88 recorded as the baseline value. Funding relies on institutional capital due to the absence of stable revenue, while patents and strict oversight create a robust defensive barrier.

EPS TTM measures the actual annual earnings per share, neutralizing the impact of security issuances or share buybacks. This indicator allows for an assessment of the business's financial viability regardless of market noise. By analyzing the trend of fundamental TTM earnings per share, an investor can see the monetization rates of Revelation Biosciences (REVB) patents. For a biotech company, this trend is critical until the completion of clinical trials and FDA approval. Growth in this metric confirms capital resilience against the debt load.